Sarah A. Cooley

764 total citations
19 papers, 598 citations indexed

About

Sarah A. Cooley is a scholar working on Immunology, Hematology and Epidemiology. According to data from OpenAlex, Sarah A. Cooley has authored 19 papers receiving a total of 598 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology, 8 papers in Hematology and 5 papers in Epidemiology. Recurrent topics in Sarah A. Cooley's work include Immune Cell Function and Interaction (12 papers), Hematopoietic Stem Cell Transplantation (8 papers) and Cytomegalovirus and herpesvirus research (5 papers). Sarah A. Cooley is often cited by papers focused on Immune Cell Function and Interaction (12 papers), Hematopoietic Stem Cell Transplantation (8 papers) and Cytomegalovirus and herpesvirus research (5 papers). Sarah A. Cooley collaborates with scholars based in United States, Sweden and United Kingdom. Sarah A. Cooley's co-authors include Jeffrey S. Miller, Bruce R. Blazar, Michael R. Verneris, Angela Panoskaltsis‐Mortari, Frank Cichocki, Martin Felices, Toshiro Niki, Valarie McCullar, Todd Lenvik and Mitsuomi Hirashima and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Sarah A. Cooley

17 papers receiving 591 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sarah A. Cooley United States	8	458	265	168	80	65	19	598
Angela R. Manser Germany	11	387 0.8×	129 0.5×	149 0.9×	56 0.7×	46 0.7×	11	527
Masayuki Takahashi Japan	10	371 0.8×	246 0.9×	148 0.9×	118 1.5×	23 0.4×	32	540
Arwen Stikvoort Sweden	12	264 0.6×	189 0.7×	131 0.8×	61 0.8×	38 0.6×	25	389
Katrin U. Lundin Norway	11	475 1.0×	287 1.1×	71 0.4×	94 1.2×	45 0.7×	12	626
Hidehiko Narazaki Japan	8	314 0.7×	261 1.0×	23 0.1×	49 0.6×	30 0.5×	21	462
Donald Gravenor United States	9	174 0.4×	214 0.8×	98 0.6×	150 1.9×	16 0.2×	24	433
Luc Meuleners Belgium	7	239 0.5×	152 0.6×	221 1.3×	39 0.5×	29 0.4×	22	562
Ahmed Gaballa Sweden	12	252 0.6×	114 0.4×	123 0.7×	40 0.5×	61 0.9×	25	352
Mizuha Kosugi‐Kanaya Japan	8	203 0.4×	85 0.3×	62 0.4×	75 0.9×	30 0.5×	14	324
Andrea Towlerton United States	10	216 0.5×	197 0.7×	168 1.0×	82 1.0×	32 0.5×	27	390

Countries citing papers authored by Sarah A. Cooley

Since Specialization

Citations

This map shows the geographic impact of Sarah A. Cooley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah A. Cooley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah A. Cooley more than expected).

Fields of papers citing papers by Sarah A. Cooley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah A. Cooley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah A. Cooley. The network helps show where Sarah A. Cooley may publish in the future.

Co-authorship network of co-authors of Sarah A. Cooley

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah A. Cooley. A scholar is included among the top collaborators of Sarah A. Cooley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah A. Cooley. Sarah A. Cooley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Geller, Melissa A., Sarah A. Cooley, Mark A. Wallet, et al.. (2020). APOLLO: A phase I study of adaptive memory natural killer (NK) cells in recurrent ovarian cancer.. Journal of Clinical Oncology. 38(15_suppl). 6044–6044. 7 indexed citations

Turcotte, Lucie M., Qing Cao, Sarah A. Cooley, et al.. (2019). Monocyte Subpopulation Recovery as Predictors of Hematopoietic Cell Transplantation Outcomes. Biology of Blood and Marrow Transplantation. 25(5). 883–890. 18 indexed citations

Bachanová, Veronika, Qing Cao, Daniel J. Weisdorf, et al.. (2019). Bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies: Results of phase I-II trial.. Journal of Clinical Oncology. 37(15_suppl). e19066–e19066. 7 indexed citations

Holstein, Sarah A., Sarah A. Cooley, Parameswaran Hari, et al.. (2019). Abstract CT108: A Phase I study of PNK-007, allogeneic, off the shelf NK cell, post autologous transplant in multiple myeloma (NCT02955550). Cancer Research. 79(13_Supplement). CT108–CT108. 1 indexed citations

Bachanová, Veronika, Daniel J. Weisdorf, Tao Wang, et al.. (2018). Donor Killer Cell Immunoglobulin-Like Receptor Genotype Does Not Improve Graft-versus-Leukemia Responses in Chronic Lymphocytic Leukemia after Unrelated Donor Transplant: A Center for International Blood and Marrow Transplant Research Analysis. Biology of Blood and Marrow Transplantation. 25(5). 949–954. 8 indexed citations

Bejanyan, Nelli, Claudio G. Brunstein, Qing Cao, et al.. (2018). Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. Blood Advances. 2(8). 909–922. 72 indexed citations

Jha, Gautam, Shilpa Gupta, Scott T. Tagawa, et al.. (2017). A phase II randomized, double-blind study of sipuleucel-T followed by IDO pathway inhibitor, indoximod, or placebo in the treatment of patients with metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 35(15_suppl). 3066–3066. 36 indexed citations

Bachanová, Veronika, Daniel J. Weisdorf, Tao Wang, et al.. (2016). Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation. Biology of Blood and Marrow Transplantation. 22(9). 1602–1607. 35 indexed citations

Holtan, Shernan G., Michael R. Verneris, Kirk R. Schultz, et al.. (2015). Circulating Angiogenic Factors Associated with Response and Survival in Patients with Acute Graft-versus-Host Disease: Results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802. Biology of Blood and Marrow Transplantation. 21(6). 1029–1036. 46 indexed citations

10.

Davis, Zachary, Sarah A. Cooley, Frank Cichocki, et al.. (2015). Adaptive Natural Killer Cell and Killer Cell Immunoglobulin–Like Receptor–Expressing T Cell Responses are Induced by Cytomegalovirus and Are Associated with Protection against Cytomegalovirus Reactivation after Allogeneic Donor Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 21(9). 1653–1662. 48 indexed citations

11.

He, Fiona, Michael R. Verneris, Sarah A. Cooley, et al.. (2014). Relationship of Epidermal Growth Factor to Cyclosporine-Assocated Magnesium Wasting and Clinical Outcomes Post-Allogeneic Hematopoietic Cell Transplantation. Blood. 124(21). 3914–3914. 1 indexed citations

12.

Holtan, Shernan G., Michael R. Verneris, Kirk R. Schultz, et al.. (2014). Circulating Angiogenic Factors As Biomarkers of Acute Gvhd Onset and Response to Therapy: Repair and Regeneration Versus Endothelial Damage and Inflammation. Blood. 124(21). 2489–2489. 1 indexed citations

13.

Fehniger, Todd A., Robert K. Stuart, Sarah A. Cooley, et al.. (2014). Preliminary Results of a Phase 1/2 Clinical Trial of Cndo-109-Activated Allogeneic Natural Killer Cells in High Risk Acute Myelogenous Leukemia Patients in First Complete Remission. Blood. 124(21). 2320–2320. 4 indexed citations

14.

Davis, Zachary, Frank Cichocki, Martin Felices, et al.. (2014). Clonal Expansion of Adaptive NK Cells and NKG2C+CD57+ KIR-Expressing T Cells from Sibling, but Not Umbilical Cord Blood, Grafts Is Induced By Recipient Latent CMV and Is Associated with Protection Against CMV Reactivation. Blood. 124(21). 181–181.

15.

Cichocki, Frank, Zachary Davis, Todd E. DeFor, et al.. (2014). CMV Reactivation is Associated with Reduced Relapse Risk, Better Disease-Free Survival and Expansion of Adaptive NK Cells after Reduced Intensity Hematopoietic Cell Transplantation. Blood. 124(21). 668–668. 2 indexed citations

16.

Rizvi, Naiyer A., Jeffrey R. Infante, Geoffrey T. Gibney, et al.. (2013). A phase I study of lirilumab (BMS-986015), an anti-KIR monoclonal antibody, administered in combination with ipilimumab, an anti-CTLA4 monoclonal antibody, in patients (Pts) with select advanced solid tumors.. Journal of Clinical Oncology. 31(15_suppl). TPS3106–TPS3106. 7 indexed citations

17.

Gleason, Michelle, Todd Lenvik, Valarie McCullar, et al.. (2012). Tim-3 Is an Inducible Human Natural Killer (NK) Cell Receptor That Enhances Interferon Gamma Production in Response to Galectin-9 (GAL-9). Biology of Blood and Marrow Transplantation. 18(2). S273–S273. 1 indexed citations

18.

Gleason, Michelle, Todd Lenvik, Valarie McCullar, et al.. (2012). Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood. 119(13). 3064–3072. 303 indexed citations

19.

Cooley, Sarah A., Xiao Feng, M. Louise M. Pitt, et al.. (2006). Expression of individual killer immunoglobulin-like receptor (KIR) genes measured by quantitative real-time-PCR divides blood natural killer (NK) cells into three developmentally distinct populations. Biology of Blood and Marrow Transplantation. 12(2). 76–77. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact